
Marina Mencinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4478111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1547-1557.	13.7	546
2	Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUS. Genomics, 1996, 37, 1-8.	2.9	144
3	Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11). Oncogene, 1999, 18, 7594-7598.	5.9	69
4	Characterization and Chromosomal Mapping of the HumanTFGGene Involved in Thyroid Carcinoma. Genomics, 1997, 41, 327-331.	2.9	42
5	Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1395, 176-180.	2.4	34
6	Characterization ofTFGinMus musculusandCaenorhabditis elegans. Biochemical and Biophysical Research Communications, 1999, 257, 67-73.	2.1	21
7	Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study Journal of Clinical Oncology, 2021, 39, 434-434.	1.6	11
8	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and Oncology, 2021, 55, 491-498.	1.7	3

2